title: [Management of myelodysplastic syndromes].
abstract: Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.
authors.affiliation: Institut Gustave-Roussy, service d'hématologie, 94805 Paris, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Duchmann
authors.affiliation: Université Paris 7, Assistance publique des Hôpitaux de Paris, hôpital Saint-Louis, service d'hématologie séniors, 75010 Paris, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.affiliation: Assistance publique des Hôpitaux de Paris, hôpital Saint-Louis, service d'hématologie, 75010 Paris, France; Centre méditerranéen de médecine moléculaire, Inserm U1065, 06204 Nice, France. Electronic address: cluzeau.thomas@gmail.com.
authors.forename: Thomas
authors.initials: T
authors.lastname: Cluzeau
mesh_terms: D000368:Aged; D000740:Anemia / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D060833:Cellular Microenvironment; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D013921:Thrombocytopenia / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents
keywords: Caractérisation; Characterization; Cytogenetic; Cytogénétique; Molecular; Moléculaire; Myelodysplastic syndrome; Syndromes myélodysplasiques; Traitement; Treatment